The evidence for the association between FPR1 and gastric cancer (GC) can be divided into two types of contrasting observations: i) FPR1 was detected in human GC specimens, and its levels are correlated with more aggressive clinical parameters and poorer outcome of patients (Cheng et al., 2014); ii) conversely, another study reports a positive association between a specific FPR1 polymorphism, which reduces receptor activity, and the increased risk of human GC (Otani et al., 2011). The gene discussed is FPR1; the disease is gastric cancer.